| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443280 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
89Zr-MAB391 and 89Zr-bevacizumab PET reflect effect of Hsp90 inhibitors and can therefore potentially be used to monitor therapeutic effects of Hsp90 inhibitor therapy in TNBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anton G.T. Terwisscha van Scheltinga, Paul Berghuis, Hilde H. Nienhuis, Hetty Timmer-Bosscha, Linda Pot, Sietske B.M. Gaykema, Marjolijn N. Lub-de Hooge, Jos G.W. Kosterink, Elisabeth G.E. de Vries, Carolien P. Schröder,